-
1
-
-
81355156238
-
Guide to receptors and channels (GRAC)
-
5th edition
-
Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
-
(2011)
Br J Pharmacol
, vol.164
, Issue.SUPPL. 1
-
-
Alexander, S.P.H.1
Mathie, A.2
Peters, J.A.3
-
2
-
-
79957551226
-
Supply and demand for endocannabinoids
-
Alger BE, Kim J, (2011). Supply and demand for endocannabinoids. Trends Neurosci 34: 304-315.
-
(2011)
Trends Neurosci
, vol.34
, pp. 304-315
-
-
Alger, B.E.1
Kim, J.2
-
3
-
-
0034189683
-
Orlistat in the treatment of obesity
-
Ballinger A, (2000). Orlistat in the treatment of obesity. Expert Opin Pharmacother 1: 841-847.
-
(2000)
Expert Opin Pharmacother
, vol.1
, pp. 841-847
-
-
Ballinger, A.1
-
4
-
-
10744229235
-
Cloning of the first sn-1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain
-
Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. (2003). Cloning of the first sn-1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163: 463-468.
-
(2003)
J Cell Biol
, vol.163
, pp. 463-468
-
-
Bisogno, T.1
Howell, F.2
Williams, G.3
Minassi, A.4
Cascio, M.G.5
Ligresti, A.6
-
5
-
-
33646472897
-
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis
-
Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, et al. (2006). Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 176: 205-212.
-
(2006)
Biochim Biophys Acta
, vol.176
, pp. 205-212
-
-
Bisogno, T.1
Cascio, M.G.2
Saha, B.3
Mahadevan, A.4
Urbani, P.5
Minassi, A.6
-
6
-
-
67049136364
-
Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol
-
Bisogno T, Burston JJ, Rai R, Allarà M, Saha B, Mahadevan A, et al. (2009a). Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 4: 946-950.
-
(2009)
ChemMedChem
, vol.4
, pp. 946-950
-
-
Bisogno, T.1
Burston, J.J.2
Rai, R.3
Allarà, M.4
Saha, B.5
Mahadevan, A.6
-
7
-
-
57649192489
-
Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo
-
Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, et al. (2009b). Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta 1791: 53-60.
-
(2009)
Biochim Biophys Acta
, vol.1791
, pp. 53-60
-
-
Bisogno, T.1
Ortar, G.2
Petrosino, S.3
Morera, E.4
Palazzo, E.5
Nalli, M.6
-
8
-
-
0346725821
-
A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase
-
Cascio MG, Minassi A, Ligresti A, Appendino G, Burstein S, Di Marzo V, (2004). A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 314: 192-196.
-
(2004)
Biochem Biophys Res Commun
, vol.314
, pp. 192-196
-
-
Cascio, M.G.1
Minassi, A.2
Ligresti, A.3
Appendino, G.4
Burstein, S.5
Di Marzo, V.6
-
9
-
-
79955396596
-
A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis
-
Chang JW, Nomura DK, Cravatt BF, (2011). A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. Chem Biol 18: 476-484.
-
(2011)
Chem Biol
, vol.18
, pp. 476-484
-
-
Chang, J.W.1
Nomura, D.K.2
Cravatt, B.F.3
-
10
-
-
43249100162
-
Targeting the endocannabinoid system: To enhance or reduce?
-
Di Marzo V, (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438-455.
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 438-455
-
-
Di Marzo, V.1
-
11
-
-
70350347327
-
CB1 antagonists for obesity - What lessons have we learned from rimonabant?
-
Di Marzo V, Després JP, (2009). CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nat Rev Endocrinol 5: 633-638.
-
(2009)
Nat Rev Endocrinol
, vol.5
, pp. 633-638
-
-
Di Marzo, V.1
Després, J.P.2
-
12
-
-
0030759362
-
Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist
-
Fernando SR, Pertwee RG, (1997). Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist. Br J Pharmacol 121: 1716-1720.
-
(1997)
Br J Pharmacol
, vol.121
, pp. 1716-1720
-
-
Fernando, S.R.1
Pertwee, R.G.2
-
14
-
-
77950647242
-
The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice
-
Higuchi S, Irie K, Mishima S, Araki M, Ohji M, Shirakawa A, et al. (2010). The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice. J Pharmacol Sci 112: 369-372.
-
(2010)
J Pharmacol Sci
, vol.112
, pp. 369-372
-
-
Higuchi, S.1
Irie, K.2
Mishima, S.3
Araki, M.4
Ohji, M.5
Shirakawa, A.6
-
15
-
-
78149411746
-
Increment of hypothalamic 2-arachidonoylglycerol induces the preference for a high-fat diet via activation of cannabinoid 1 receptors
-
Higuchi S, Ohji M, Araki M, Furuta R, Katsuki M, Yamaguchi R, et al. (2011). Increment of hypothalamic 2-arachidonoylglycerol induces the preference for a high-fat diet via activation of cannabinoid 1 receptors. Behav Brain Res 216: 477-480.
-
(2011)
Behav Brain Res
, vol.216
, pp. 477-480
-
-
Higuchi, S.1
Ohji, M.2
Araki, M.3
Furuta, R.4
Katsuki, M.5
Yamaguchi, R.6
-
16
-
-
84858990388
-
Cannabinoid-1 receptor (CB1R) blockers as medicines: Beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists
-
Janero DR, (2012). Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists. Expert Opin Emerg Drugs 17: 17-29.
-
(2012)
Expert Opin Emerg Drugs
, vol.17
, pp. 17-29
-
-
Janero, D.R.1
-
17
-
-
84858067148
-
2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism
-
Jung KM, Clapper JR, Fu J, D'Agostino G, Guijarro A, Thongkham D, et al. (2012). 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab 15: 299-310.
-
(2012)
Cell Metab
, vol.15
, pp. 299-310
-
-
Jung, K.M.1
Clapper, J.R.2
Fu, J.3
D'Agostino, G.4
Guijarro, A.5
Thongkham, D.6
-
18
-
-
77954326944
-
NC3Rs Reporting Guidelines Working Group
-
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
-
(2010)
Br J Pharmacol
, vol.160
, pp. 1577-1579
-
-
Kilkenny, C.1
Browne, W.2
Cuthill, I.C.3
Emerson, M.4
Altman, D.G.5
-
19
-
-
57749087828
-
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
-
Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
-
(2009)
Nat Chem Biol
, vol.5
, pp. 37-44
-
-
Long, J.Z.1
Li, W.2
Booker, L.3
Burston, J.J.4
Kinsey, S.G.5
Schlosburg, J.E.6
-
20
-
-
78650962985
-
Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus
-
Ludányi A, Hu SS, Yamazaki M, Tanimura A, Piomelli D, Watanabe M, et al. (2011). Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience 174: 50-63.
-
(2011)
Neuroscience
, vol.174
, pp. 50-63
-
-
Ludányi, A.1
Hu, S.S.2
Yamazaki, M.3
Tanimura, A.4
Piomelli, D.5
Watanabe, M.6
-
21
-
-
77954331629
-
Guidelines for reporting experiments involving animals: The ARRIVE guidelines
-
McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
-
(2010)
Br J Pharmacol
, vol.160
, pp. 1573-1576
-
-
McGrath, J.1
Drummond, G.2
Kilkenny, C.3
Wainwright, C.4
-
22
-
-
0036682222
-
The endogenous cannabinoid system controls extinction of aversive memories
-
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
-
(2002)
Nature
, vol.418
, pp. 530-534
-
-
Marsicano, G.1
Wotjak, C.T.2
Azad, S.C.3
Bisogno, T.4
Rammes, G.5
Cascio, M.G.6
-
23
-
-
0033839170
-
Cannabinoid properties of methylfluorophosphonate analogs
-
Martin BR, Beletskaya I, Patrick G, Jefferson R, Winckler R, Deutsch DG, et al. (2000). Cannabinoid properties of methylfluorophosphonate analogs. J Pharmacol Exp Ther 294: 1209-1218.
-
(2000)
J Pharmacol Exp Ther
, vol.294
, pp. 1209-1218
-
-
Martin, B.R.1
Beletskaya, I.2
Patrick, G.3
Jefferson, R.4
Winckler, R.5
Deutsch, D.G.6
-
24
-
-
50649106505
-
Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats
-
Mathes CM, Ferrara M, Rowland NE, (2008). Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. Am J Physiol Regul Integr Comp Physiol 295: R67-R75.
-
(2008)
Am J Physiol Regul Integr Comp Physiol
, vol.295
-
-
Mathes, C.M.1
Ferrara, M.2
Rowland, N.E.3
-
25
-
-
0029012014
-
Compton, identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
-
Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. (1995). Compton, identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
-
(1995)
Biochem Pharmacol
, vol.50
, pp. 83-90
-
-
Mechoulam, R.1
Ben-Shabat, S.2
Hanus, L.3
Ligumsky, M.4
Kaminski, N.E.5
Schatz, A.R.6
-
26
-
-
56249108088
-
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism
-
Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V, (2008). Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem 51: 6970-6979.
-
(2008)
J Med Chem
, vol.51
, pp. 6970-6979
-
-
Ortar, G.1
Bisogno, T.2
Ligresti, A.3
Morera, E.4
Nalli, M.5
Di Marzo, V.6
-
27
-
-
43949121784
-
Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond
-
Pertwee RG, (2008). Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13: 147-159.
-
(2008)
Addict Biol
, vol.13
, pp. 147-159
-
-
Pertwee, R.G.1
-
28
-
-
0031902759
-
SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset
-
Simiand J, Keane M, Keane PE, Soubrié P, (1998). SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9: 179-181.
-
(1998)
Behav Pharmacol
, vol.9
, pp. 179-181
-
-
Simiand, J.1
Keane, M.2
Keane, P.E.3
Soubrié, P.4
-
29
-
-
80052273507
-
Distribution of diacylglycerol lipase alpha, an endocannabinoid synthesizing enzyme, in the rat forebrain
-
Suárez J, Ortíz O, Puente N, Bermúdez-Silva FJ, Blanco E, Fernández-Llebrez P, et al. (2011). Distribution of diacylglycerol lipase alpha, an endocannabinoid synthesizing enzyme, in the rat forebrain. Neuroscience 192: 112-131.
-
(2011)
Neuroscience
, vol.192
, pp. 112-131
-
-
Suárez, J.1
Ortíz, O.2
Puente, N.3
Bermúdez-Silva, F.J.4
Blanco, E.5
Fernández-Llebrez, P.6
-
30
-
-
0028970517
-
2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
-
Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
-
(1995)
Biochem Biophys Res Commun
, vol.215
, pp. 89-97
-
-
Sugiura, T.1
Kondo, S.2
Sukagawa, A.3
Nakane, S.4
Shinoda, A.5
Itoh, K.6
-
31
-
-
79959653392
-
Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies
-
Ward SJ, Raffa RB, (2011). Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring) 19: 1325-1334.
-
(2011)
Obesity (Silver Spring)
, vol.19
, pp. 1325-1334
-
-
Ward, S.J.1
Raffa, R.B.2
|